Theravance Biopharma TBPH
NASDAQ TBPH
$17.08 +0.00 (+0.00%)
As of: Sep 4, 2026 · 3:59 PM EDT

Theravance Biopharma (TBPH) Cash from Discontinued Operations (2021 - 2022)

Theravance Biopharma (TBPH) posted quarterly Cash from Discontinued Operations of 178968000.0 for Q4 2022, down 6455.4% year-over-year from 2816000.0 in Q4 2021, and down 3335.75% quarter-over-quarter from 5209000.0 in Q3 2022.

Analysis

Theravance Biopharma (TBPH) Cash from Discontinued Operations (2021 - 2022) Analysis & Trends

Theravance Biopharma (TBPH) has reported Cash from Discontinued Operations for 2 consecutive years, with 178968000.0 the latest figure, recorded in Q4 2022.

  • In Q4 2022, Cash from Discontinued Operations fell 6455.4% year-over-year to 178968000.0; the TTM figure through Dec 2022 stood at 184566000.0 (changed N/A YoY), while the FY2022 annual figure was 184566000.0, down 761.12% from the prior year.
  • Cash from Discontinued Operations eased to 178968000.0 in Q4 2022 per TBPH's latest filing, from 5209000.0 in the prior quarter.
  • Across five years, Cash from Discontinued Operations topped out at 2816000.0 in Q4 2021 and bottomed at 178968000.0 in Q4 2022.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Discontinued Operations (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn -
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn -
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn -
5 Revolution Medicines 44.33 Bn 44.33 Bn - -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn -
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn -
8 Royalty Pharma 28.45 Bn 27.61 Bn - -
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn -
10 Theravance Biopharma 882.99 Mn 495.33 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2022 -178.97 Mn
Sep 30, 2022 -5.21 Mn
Jun 30, 2022 -1.00 Mn
Mar 31, 2022 615,000.00
Dec 31, 2021 2.82 Mn